The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 18 January 2005, www.theannals.com, DOI 10.1345/aph.1E334.
 The Annals of Pharmacotherapy: Vol. 39, No. 3, pp. 502-507. DOI 10.1345/aph.1E334
© 2005 Harvey Whitney Books Company.
This Article
Right arrow Abstract Freely available
Right arrow Résumé Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goldman-Levine, J. D
Right arrow Articles by Lee, K. W
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goldman-Levine, J. D
Right arrow Articles by Lee, K. W

NEW DRUG DEVELOPMENTS

OBJETIVO: El análisis de la farmacología, la farmacocinética, los datos de ensayos clínicos, los efectos adversos, y del papel de la insulina detemir en el tratamiento de la diabetes mellitus.

FUENTES DE INFORMACIÓN: Los artículos y los extractos de congresos identificados a través de búsquedas en las bases de datos de MEDLINE (1996 a junio del 2004), de EMBASE (1980 a junio del 2004), y de International Pharmaceutical Abstracts (1970 a junio del 2004), además de información no publicada proporcionada por el fabricante.

SELECCIÓN DE FUENTES Y MÉTODO DE EXTRACCIÓN DE LA INFORMACIÓN: Se seleccionaron todos los estudios disponibles relacionados con la farmacología de la insulina detemir. Sólo los estudios en humanos fueron utilizados para obtener los datos farmacocinéticos, de interacción de fármacos, de eficacia, y de seguridad.

SÍNTESIS: La insulina detemir es un análogo de la insulina basal que ha mostrado mejorar el control glúcemico en pacientes con diabetes tipo 1 y 2.

CONCLUSIONES: La insulina detemir ofrece ciertos beneficios sobre NPH para el uso como insulina basal en pacientes con diabetes tipo 1 y 2.

www.theannals.com, DOI 10.1345/aph.1E334


This article has been cited by other articles:


Home page
 Anesth. Analg.Home page
R. P. Olson, M. A. Bethel, and L. Lien
Preoperative Hypoglycemia in a Patient Receiving Insulin Detemir
Anesth. Analg., June 1, 2009; 108(6): 1836 - 1838.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
M. C. Jones and M. Patel
Insulin detemir: A long-acting insulin product
Am. J. Health Syst. Pharm., December 15, 2006; 63(24): 2466 - 2472.
[Abstract] [Full Text] [PDF]

Home page
 EDUCATION AND PRACTICEHome page
F. M Regan and D. B Dunger
Use of new insulins in children
Arch. Dis. Child. Ed. Pract., August 1, 2006; 91(2): ep47 - ep53.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Résumé Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goldman-Levine, J. D
Right arrow Articles by Lee, K. W
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goldman-Levine, J. D
Right arrow Articles by Lee, K. W

homecopy help contact us subscription past issues search current issue
Copyright © 2005 by Harvey Whitney Books Company.